| Literature DB >> 30865069 |
Thomas Copperman1, Oluwatobi O Idowu, Robert C Kersten, M Reza Vagefi.
Abstract
Intravenous tocilizumab has been demonstrated to be an effective disease modifying agent in the treatment of moderate to severe active thyroid eye disease. The authors describe 2 patients treated with tocilizumab using home subcutaneous administration over an accelerated, biweekly course. Both patients exhibited improvement in thyroid eye disease clinical activity and proptosis.Entities:
Mesh：
Substances：
Year: 2019 PMID： 30865069 DOI： 10.1097/IOP.0000000000001346
Source DB: PubMed Journal: Ophthalmic Plast Reconstr Surg ISSN： 0740-9303 Impact factor: 1.746